Harnessing the immune system against leukemia: Monoclonal antibodies and checkpoint strategies for AML

Advances in Experimental Medicine and Biology

Volumn 995, Issue , 2017, Pages 73-95

  Masarova, Lucia ^a   Kantarjian, Hagop ^a   Garcia Mannero, Guillermo ^a   Ravandi, Farhad ^a   Sharma, Padmanee ^a   Daver, Naval ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute myeloid leukemia; Immune checkpoint blockade; Immunotherapy; Monoclonal antibody

Indexed keywords

ANTINEOPLASTIC AGENT; AVE 9633; CALICHEAMICIN; CHIMERIC ANTIGEN RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DIPHTHERIA TOXIN INTERLEUKIN 3; GEMTUZUMAB OZOGAMICIN; IPILIMUMAB; LINTUZUMAB; LORVOTUZUMAB MERTANSINE; MAYTANSINE; MONOCLONAL ANTIBODY; NIVOLUMAB; T LYMPHOCYTE ANTIBODY; UNCLASSIFIED DRUG; TUMOR MARKER;

ACUTE MYELOID LEUKEMIA; CANCER IMMUNOTHERAPY; CLINICAL STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE MARKER; HUMAN; IMMUNE SYSTEM; IMMUNOCYTOTOXICITY; LEUKEMIA CELL; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); TUMOR CELL; ADOPTIVE IMMUNOTHERAPY; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIBODY SPECIFICITY; DRUG EFFECTS; IMMUNOLOGY; IMMUNOTHERAPY; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MICROBIOLOGY; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROCEDURES; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TRANSPLANTATION; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; LEUKEMIA, MYELOID, ACUTE; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 85015820613     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-3-319-53156-4_4     Document Type: Chapter

References (103)

1. Yates JW, Wallace Jr HJ, Ellison RR, Holland JF. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep. 1973;57(4):485–8.
2. Kantarjian H, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006;106(5):1090–8. doi:10.1002/cncr.21723.
3. Kantarjian HM. Therapy for elderly patients with acute myeloid leukemia: a problem in search of solutions. Cancer. 2007;109(6):1007–10. doi:10.1002/cncr.22502.
4. Giles F, et al. Outcome of patients with acute myelogenous leukemia after second salvage therapy. Cancer. 2005;104(3):547–54. doi:10.1002/cncr.21187.
5. Ravandi F, et al. (2010) Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy. Blood 116(26):5818–23; quiz 6153. doi:10.1182/blood-2010-07-296392
6. Horowitz MM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75(3):555–62.
7. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol. 2005;23(9):1147–57. doi:10.1038/nbt1137.
8. Shuptrine CW, Surana R, Weiner LM. Monoclonal antibodies for the treatment of cancer. Semin Cancer Biol. 2012;22(1):3–13. doi:10.1016/j.semcancer.2011.12.009.
9. Saito Y, et al. Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci Transl Med. 2010;2(17):17ra9. doi:10.1126/scitranslmed.3000349.
10. Freeman SD, Kelm S, Barber EK, Crocker PR. Characterization of CD33 as a new member of the sialoadhesin family of cellular interaction molecules. Blood. 1995;85(8):2005–12.
11. Guo W, et al. Numbers and cytotoxicities of CD3 + CD56+ T lymphocytes in peripheral blood of patients with acute myeloid leukemia and acute lymphocytic leukemia. Cancer Biol Ther. 2013;14(10):916–21. doi:10.4161/cbt.25938.
12. Munoz L, et al. Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies. Haematologica. 2001;86(12):1261–9.
13. Hauswirth AW, et al. Expression of the target receptor CD33 in CD34+/CD38−/CD123+ AML stem cells. Eur J Clin Invest. 2007;37(1):73–82. doi:10.1111/j.1365-2362.2007.01746.x.
14. Raza A, et al. Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial. Leuk Lymphoma. 2009;50(8):1336–44. doi:10.1080/10428190903050013.
15. Feldman EJ, et al. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol. 2005;23(18):4110–6. doi:10.1200/jco.2005.09.133.
16. Sekeres MA, et al. Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia. Haematologica. 2013;98(1):119–28. doi:10.3324/haematol.2012.066613.
17. Vasu SHS, Cheney C, Gopalakrishnan B, Mani R, Lozanski G, Mo X. Decitabine upregulates surface expression of ligands for NK activating receptors in AML blasts resulting in increased efficacy of the novel CD33-specifci Fc-engineered antibody BI 836858 against primary AML blasts –a rational for combination therapy. Blood. 2016;127(23):2879–89.
18. Lapusan S, et al. Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. Invest New Drugs. 2012;30(3):1121–31. doi:10.1007/s10637-011-9670-0.
19. Bross PF, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001;7(6):1490–6.
20. Sievers EL, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19(13):3244–54.
21. Larson RA, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer. 2005;104(7):1442–52. doi:10.1002/cncr.21326.
22. Petersdorf SH, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121(24):4854–60. doi:10.1182/blood-2013-01-466706.
23. McKoy JM, et al. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res. 2007;31(5):599–604. doi:10.1016/j.leukres.2006.07.005.
24. Rajvanshi P, Shulman HM, Sievers EL, McDonald GB. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood. 2002;99(7):2310–4.
25. Burnett AK, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2011;29(4):369–77. doi:10.1200/jco.2010.31.4310.
26. Burnett AK, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol. 2012;30(32):3924–31. doi:10.1200/jco.2012.42.2964.
27. Castaigne S, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet (London, England). 2012;379(9825):1508–16. doi:10.1016/s0140-6736(12)60485-1.
28. Hills RK, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014;15(9):986–96. doi:10.1016/s1470-2045(14)70281-5.
29. Ravandi F, et al. Gemtuzumab ozogamicin: time to resurrect? J Clin Oncol. 2012;30(32):3921–3. doi:10.1200/jco.2012.43.0132.
30. Rowe JM, Lowenberg B. Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug. Blood. 2013;121(24):4838–41. doi:10.1182/blood-2013-03-490482.
31. Kung Sutherland MS, et al. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood. 2013;122(8):1455–63. doi:10.1182/blood-2013-03-491506.
32. Sutherland MK, et al. 5-azacytidine enhances the anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia. mAbs. 2010;2(4):440–8.
33. Fathi A Erba HP, Lancet JE, Stein B, Walter R, DeAngelo D. (2015) SGN-CD33A plus hypomethylating agents: a novel, well-tolerated regimen with high remission rate in frontline unfit AML. Blood 126(Abst. 454).
34. Watkins K WR, Fishkin N, Audette Ch, Kovtun Y, Romanelli A (2015) IMGN779, a CD33-targeted antibody-drug conjugate (ADC) with a novel DNA-alkylating effector molecule, induces DNA damage, cell cycle arrest, and apoptosis in AML cells. ASH Abstract No 1366.
35. Whiteman KR, et al. Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models. mAbs. 2014b;6(2):556–66. doi:10.4161/mabs.27756.
36. Whiteman KR NP, Walker R, Watkins K, Kovtun Y, Harvey L, Wilhelm A, et al. (2014a) The antibody-drug conjugate (ADC) IMGN779 is highly active in vitro and in vivo against acute myeloid leukemia (AML) with FLT3-ITD mutations. ASH Abstract No 2321.
37. Bagley CJ, Woodcock JM, Stomski FC, Lopez AF. The structural and functional basis of cytokine receptor activation: lessons from the common beta subunit of the granulocyte-macrophage colony-stimulating factor, interleukin-3 (IL-3), and IL-5 receptors. Blood. 1997;89(5):1471–82.
38. Testa U, et al. Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood. 2002;100(8):2980–8. doi:10.1182/blood-2002-03-0852.
39. He SZ, et al. A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia. Leuk Lymphoma. 2015;56(5):1406–15. doi:10.3109/10428194.2014.956316.
40. Smith BD RJ, Walter RB, et al. (2014) 120 First-in Man, Phase 1 Study of CSL362 (Anti-IL3Rα/ Anti-CD123 monoclonal antibody) in patients with CD123+ acute myeloid leukemia (AML) in CR at high risk for early relapse. Blood. Abstract 616
41. Frankel AE, Ramage J, Kiser M, Alexander R, Kucera G, Miller MS. Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor. Protein Eng. 2000;13(8):575–81.
42. Frankel AE, et al. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014;124(3):385–92. doi:10.1182/blood-2014-04-566737.
43. Konopleva M HD, Rizzieri D, Cirrito T, Liu JS, Kornblau S, Grable M, Hwang IL, Borthakur G, et al. (2010) Phase I trial results for SL-401, a novel cancer stem cell (CSC) targeting agent, demonstrate clinical efficacy at tolerable doses in patients with heavily pre-treated AML, poor risk elderly AML, and high risk MDS. 53th ASH Annual Meeting and Exposition Abstract No 3298.
44. Pemmaraju N, Lane A, Sweet K, Stein A, Vasu S, Konopleva M, et al. Results from ongoing phase 2 registration study of SL-401 in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). EHA 2016, Abstract S812.
45. Sweet K PN, Lane A, Stein A, Vasu S, Blum W, Rizzieri DA, et al. (2015) Lead-in stage results of a pivotal trial of SL-401, an interleukin-3 receptor (IL-3R) targeting biologic, in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) or acute myeloid leukemia (AML) ASH 2015 Abstract No 3795
46. Zeromski J, Nyczak E, Dyszkiewicz W. Significance of cell adhesion molecules, CD56/ NCAM in particular, in human tumor growth and spreading. Folia Histochem Cytobiol. 2001;39(Suppl 2):36–7.
47. Cunningham BA, Hemperly JJ, Murray BA, Prediger EA, Brackenbury R, Edelman GM. Neural cell adhesion molecule: structure, immunoglobulin-like domains, cell surface modulation, and alternative RNA splicing. Science (New York, NY). 1987;236(4803):799–806.
48. Patel K, et al. Neural cell adhesion molecule (NCAM) is the antigen recognized by monoclonal antibodies of similar specificity in small-cell lung carcinoma and neuroblastoma. Int J Cancer. 1989;44(4):573–8.
49. Erickson HK, Lambert JM. ADME of antibody-maytansinoid conjugates. AAPS J. 2012;14(4):799–805. doi:10.1208/s12248-012-9386-x.
50. Shah MH, et al. Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors. Invest New Drugs. 2016;34(3):290–9. doi:10.1007/s10637-016-0336-9.
51. Clift RA, et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood. 1990;76(9):1867–71.
52. Scheinberg DA, et al. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. J Clin Oncol. 1991;9(3):478–90.
53. Burke JM, et al. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias. Bone Marrow Transplant. 2003;32(6):549–56. doi:10.1038/sj.bmt.1704201.
54. Matthews DC, et al. Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood. 1999;94(4):1237–47.
55. Pagel JM, et al. 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood. 2006;107(5):2184–91. doi:10.1182/blood-2005-06-2317.
56. Rosenblat TL, et al. Sequential cytarabine and alpha-particle immunotherapy with bismuth-213- lintuzumab (HuM195) for acute myeloid leukemia. Clin Cancer Res. 2010;16(21):5303–11. doi:10.1158/1078-0432.ccr-10-0382.
57. Jurcic JG RT, McDevitt MR, et al. (2011) Phase I trial of the targeted alpha-particle nano-generator Actinium-225(225Ac)-Lintuzumab (anti-CD33; HuM195) in acute myeloid leukemia (AML). ASH Abstract No 768
58. Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 2009;69(12):4941–4. doi:10.1158/0008-5472.can-09-0547.
59. Topp MS, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29(18):2493–8. doi:10.1200/jco.2010.32.7270.
60. Krupka C, et al. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. Blood. 2014;123(3):356–65. doi:10.1182/blood-2013-08-523548.
61. Laszlo GS, et al. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. Blood. 2014;123(4):554–61. doi:10.1182/blood-2013-09-527044.
62. Rader C. DARTs take aim at BiTEs. Blood. 2011;117(17):4403–4. doi: 10.1182/blood-2011-02-337691.
63. Chichili GR, et al. A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates. Sci Transl Med. 2015;7(289):289ra82. doi:10.1126/scitranslmed.aaa5693.
64. Knuth A, Danowski B, Oettgen HF, Old LJ. T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures. Proc Natl Acad Sci U S A. 1984;81(11):3511–5.
65. Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science (New York, NY). 2015;348(6230):62–8. doi:10.1126/science.aaa4967.
66. Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A. 1989;86(24):10024–8.
67. Pegram HJ, Park JH, Brentjens RJ. CD28z CARs and armored CARs. Cancer journal (Sudbury, MA). 2014;20(2):127–33. doi:10.1097/ppo.0000000000000034.
68. Grupp SA, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509–18. doi:10.1056/NEJMoa1215134.
69. Ritchie DS, et al. Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol Ther. 2013;21(11):2122–9. doi:10.1038/mt.2013.154.
70. Pizzitola I, et al. Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. Leukemia. 2014;28(8):1596–605. doi:10.1038/leu.2014.62.
71. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64. doi:10.1038/nrc3239.
72. Motz GT, Coukos G. Deciphering and reversing tumor immune suppression. Immunity. 2013;39(1):61–73.
73. Kirkwood JM, Tarhini AA, Panelli MC, Moschos SJ, Zarour HM, Butterfield LH, Gogas HJ. Next generation of immunotherapy for melanoma. J Clin Oncol. 2008;26(20):3445–55.
74. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734–6.
75. Linsley PS, Greene JL, Brady W, Bajorath J, Ledbetter JA, Peach R. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity. 1994;1(9):793–801.
76. Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11(2):141–51.
77. Velu V, et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature. 2009;458(7235):206–10. doi:10.1038/nature07662.
78. Dong H, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793–800. doi:10.1038/nm730.
79. Barber DL, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439(7077):682–7. doi:10.1038/nature04444.
80. Hodi FS, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23. doi:10.1056/NEJMoa1003466.
81. Page DB, Postow MA, Callahan MK, Allison JP, Wolchok JD. Immune modulation in cancer with antibodies. Annu Rev Med. 2014;65:185–202. doi:10.1146/Annurev-Med-092012-112807.
82. Robert C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–26. doi:10.1056/NEJMoa1104621.
83. Andorsky DJ, Yamada RE, Said J, Pinkus GS, Betting DJ, Timmerman JM. Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumorassociated T cells. Clin Cancer Res. 2011;17(13):4232–44. doi:10.1158/1078-0432.ccr-10-2660.
84. Costello RT, Mallet F, Sainty D, Maraninchi D, Gastaut JA, Olive D. Regulation of CD80/ B7-1 and CD86/B7-2 molecule expression in human primary acute myeloid leukemia and their role in allogenic immune recognition. Eur J Immunol. 1998;28(1):90–103. doi:10.1002/ (SICI)1521-4141(199801)28:01<90::AID-IMMU90>3.0.CO;2-5.
85. Graf M, et al. High expression of costimulatory molecules correlates with low relapse-free survival probability in acute myeloid leukemia (AML). Ann Hematol. 2005;84(5):287–97. doi:10.1007/s00277-004-0978-0.
86. Re F, et al. Expression of CD86 in acute myelogenous leukemia is a marker of dendritic/ monocytic lineage. Exp Hematol. 2002;30(2):126–34.
87. Vollmer M, et al. Expression of human leucocyte antigens and co-stimulatory molecules on blasts of patients with acute myeloid leukaemia. Br J Haematol. 2003;120(6):1000–8.
88. Whiteway A, Corbett T, Anderson R, Macdonald I, Prentice HG. Expression of co-stimulatory molecules on acute myeloid leukaemia blasts may effect duration of first remission. Br J Haematol. 2003;120(3):442–51.
89. Fevery S, et al. CTLA-4 blockade in murine bone marrow chimeras induces a host-derived antileukemic effect without graft-versus-host disease. Leukemia. 2007;21(7):1451–9. doi:10.1038/sj.leu.2404720.
90. Mumprecht S, Schurch C, Schwaller J, Solenthaler M, Ochsenbein AF. Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood. 2009;114(8):1528–36. doi:10.1182/blood-2008-09-179697.
91. Zhang L, Gajewski TF, Kline J. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood. 2009;114(8):1545–52. doi:10.1182/blood-2009-03-206672.
92. Zhou Q, et al. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood. 2011;117(17):4501–10. doi:10.1182/blood-2010-10-310425.
93. Koestner W, et al. PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells. Blood. 2011;117(3):1030–41. doi:10.1182/blood-2010-04-283119.
94. Zhou Q, et al. Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. Blood. 2010;116(14):2484–93. doi:10.1182/blood-2010-03-275446.
95. Daver N, Basu S, Garcia-Manero G, Cortes J, Ravandi F, Ning J, Sharma P, et al. Defining the Immune Checkpoint Landscape in Patients with Acute Myeloid Leukemia. Blood 2016; 128:2900.
96. Berger R, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res. 2008;14(10):3044–51. doi:10.1158/1078-0432.CCR-07-4079.
97. Yang H, et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 2013; doi:10.1038/leu.2013.355.
98. Daver N, Basu S, Garcia-Manero G, Cortes J, Ravandi F, Sharma P, et al. Phase IB/II Study of Nivolumab in Combination with 5-Azacitidine in Patients with Relapsed Acute Myeloid Leukemia. Blood 2016;128:763
99. Davids MS KH, Costello CL, McSweeney PA, Liguori R, Lukez A, et al. (2015) A multicenter phase I/Ib study of ipilimumab for relapsed hematologic malignancies after allogeneic hematopoietic stem cell transplantation. ASH Abstract No 723
100. Richter G, Burdach S. ICOS: a new costimulatory ligand/receptor pair and its role in T-cell activion. Onkologie. 2004;27(1):91–5. doi:10.1159/000075612.
101. Richter G, et al. Tumor necrosis factor-alpha regulates the expression of inducible costimulator receptor ligand on CD34(+) progenitor cells during differentiation into antigen presenting cells. J Biol Chem. 2001;276(49):45686–93. doi:10.1074/jbc.M108509200.
102. Wang C, Lin GH, McPherson AJ, Watts TH. Immune regulation by 4-1BB and 4-1BBL: complexities and challenges. Immunol Rev. 2009;229(1):192–215. doi:10.1111/j.1600-065X.2009.00765.x.
103. Imura A, et al. OX40 expressed on fresh leukemic cells from adult T-cell leukemia patients mediates cell adhesion to vascular endothelial cells: implication for the possible involvement of OX40 in leukemic cell infiltration. Blood. 1997;89(8):2951–8.